Botechnology company Ridgeback Biotherapeutics LP said on Wednesday that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its investigational Ebola treatment, ansuvimab (mAb114), and granted priority review designation.
Ansuvimab is a monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, Democratic Republic of the Congo.
According to Wendy Holman, CEO and co-founder of Ridgeback, the treatment has demonstrated "an impressive survival benefit" in Ebola patients.
The FDA previously granted Breakthrough Therapy Designation status to ansuvimab as a treatment for Ebola in September 2019.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial